Insider Selling: Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) CEO Sells $1,002,909.56 in Stock

Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) CEO Peter George Colis sold 29,342 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $34.18, for a total value of $1,002,909.56. Following the completion of the transaction, the chief executive officer directly owned 1,565,960 shares of the company’s stock, valued at approximately $53,524,512.80. This trade represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ethos Technologies Inc. Class A Common Stock Price Performance

Shares of NASDAQ:LIFE opened at $33.52 on Friday. The stock has a market capitalization of $2.14 billion and a P/E ratio of -11.76. Ethos Technologies Inc. Class A Common Stock has a 52-week low of $9.45 and a 52-week high of $35.69. The firm has a fifty day moving average of $22.13.

Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.34. The company had revenue of $189.56 million for the quarter. Ethos Technologies Inc. Class A Common Stock’s revenue was up 113.5% on a year-over-year basis. Sell-side analysts forecast that Ethos Technologies Inc. Class A Common Stock will post -2.13 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Ethos Technologies Inc. Class A Common Stock stock. Philadelphia Investment Partners LLC acquired a new position in shares of Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 3,847 shares of the company’s stock, valued at approximately $69,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on LIFE. Citizens Jmp upped their price objective on shares of Ethos Technologies Inc. Class A Common Stock from $27.00 to $33.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 4th. Robert W. Baird boosted their price target on Ethos Technologies Inc. Class A Common Stock from $26.00 to $32.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. William Blair set a $33.00 price target on Ethos Technologies Inc. Class A Common Stock in a research note on Tuesday, August 4th. Barclays raised their price objective on Ethos Technologies Inc. Class A Common Stock from $27.00 to $37.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings lowered Ethos Technologies Inc. Class A Common Stock from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 26th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $32.29.

Ethos Technologies Inc. Class A Common Stock Company Profile

Ethos Technologies Inc operates a technology-driven, direct-to-consumer platform for the distribution of life insurance products. Through its digital underwriting, data analytics, and proprietary technology, it enables consumers to explore, compare, and purchase life insurance policies online. The platform serves consumers, agents, and insurance carriers, and supports the application and policy issuance process through an online interface. The company works with insurance carriers to offer life insurance products in the United States through digital channels and independent agents.